Effectiveness of early intervention with Jin-long capsules and transarterial chemoembolization for the treatment of primary liver cancer
-
摘要:
目的 观察金龙胶囊先期干预联合肝动脉栓塞介入化疗(transcatheter arterial chemoembolization, TACE)治疗原发性肝癌的临床疗效。 方法 将70例原发性肝癌患者随机分为两组, 单纯TACE组36例(对照组), TACE+金龙胶囊组34例(治疗组)。对照组进行E-ADM+5-FU+DDP TACE治疗1次; 治疗组在对照组的基础上, 于治疗前7天始口服金龙胶囊1 g/次, 3次/日, 连续服用5周。观察两组治疗后肿瘤病灶大小、肝功能指标、中医证候评分、KPS评分及Th1、Th2细胞因子漂移等方面的变化情况。 结果 在肿瘤病灶大小变化、肝功能评价指标数值变化、KPS评分值、中医症状评分及Th1、Th2细胞因子浓度变化等多方面, 单纯TACE组与金龙胶囊先期干预组比较, 有显著性统计学差异(P < 0.05)。 结论 研究资料显示金龙胶囊先期干预对原发性肝癌具有抑制肿瘤、减毒增效保肝、提高生存质量、增强免疫功能等疗效, 且经证实无出血及凝血功能障碍等不良反应。 Abstract:Objective The objective of this study was to observe the clinical effects of early treatment with Jin-long capsules combined with transarterial chemoembolization(TACE) in primary liver cancer. Methods Seventy patients with primary liver cancer were randomly divided into two groups, namely, the contrast group(administered with TACE only) and the treatment group(given TACE and Jin-long capsules).The contrast group received TACE treatment with E-ADM + 5-Fu + DDP once.By contrast, the treatment group was given 1 g of Jin-long capsules initially and thrice a day before the 7-day TACE regimen began, which lasted for 5 weeks(continuously). Results The two groups significantly differed in their tumor lesion size, liver function index, TCM symptomatic score, KPS score, and cytokine switching of Th1 and Th2(P < 0.05). Conclusions Clinical research shows that early intervention with Jin-long capsules for primary liver cancer can improve the efficiency of anticancer therapy, minimize adverse reactions, as well as protect the liver, improve the quality of life, and enhance the immune function of patients.Jin-long capsules have no adverse reactions, such as bleeding and coagulation disorders. -
Key words:
- jin-long capsules /
- primary liver cancer /
- TACE /
- liver dysfunction /
- early intervention
-
表 1 两组TACE治疗后4周肿瘤原发病灶比较 例（%）
Table 1. Comparison of primary tumor lesions after 4 weeks of TACE treatment in the study groups n(%)
表 2 TACE治疗前后ALT、TBIL及ALB的变化
Table 2. Changes in ALT, TBIL, and ALB before and after TACE treatment
表 3 两组患者治疗前后卡氏评分情况比较
Table 3. Comparison of Karnofsky scores before and after treatment in the study groups
表 4 两组患者TACE治疗后4周中医症状改善情况比较
Table 4. Comparison of improvements in traditional Chinese medicine symptoms after 4 weeks of TACE treatment in the study groups
表 5 金龙胶囊联合TACE对HCC患者Th1和Th2水平的影响（ng/ L，x±s）
Table 5. Effects of treatment with Jin-long capsules combined with TACE on Th1 and Th2 levels
-
[1] Dank M. Treatment of primary hepatocellular carcinoma[J]. OrvHetil, 2010, 151(36): 1445-1449. doi: 10.1556/oh.2010.28953 [2] Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer inci dence and mortality worldwide IARC Cancer Base No. 10[M/OL] Lyon, France//International Agency for Research on Cancer, 2010. [3] Zhang JW, Feng XY, Liu HQ, et al. CT volume measurement for prognostic evaluation of unresectable hepatocellular carcinoma af ter TACE[J]. World J Gastroenterol, 2010, 16(16): 2038-2045. doi: 10.3748/wjg.v16.i16.2038 [4] 郑筱萸, 主编. 中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社, 2000: 192. [5] 高姗, 杨万水, 张薇, 等. 原发性肝癌全人群生存率的分析和比较[J]. 肿瘤, 2010, 30(12): 1027-1032. doi: 10.3781/j.issn.1000-7431.2010.12.007 [6] 许飞, 王永涛, 史仲华, 等. 多次肝动脉化疗栓塞术对原发性肝癌的疗效及对肝功能的影响[J]. 肿瘤学杂志, 2011, 17(11): 850-853. https://www.cnki.com.cn/Article/CJFDTOTAL-XHON201111016.htm [7] 曹强, 荣阳. 肝癌介入性化疗栓塞术后严重并发症分析研究[J]. 影像与介入, 2012, 19(3): 109-111. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201203067.htm [8] 姜家康, 陈瑞睿, 刘洪星, 等. 关于"肝之癌毒"理论的简述[J]. 中医药信息, 2012, 29(4): 12-13. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXN201204007.htm [9] 田甜, 张培彤, 于明薇, 等. 4种活血化瘀药物对不同阶段Lewis肺癌生长和转移影响的实验研究[J]. 辽宁中医杂志, 2010, 37(3): 546-548. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY201003091.htm [10] 郭尹玲, 钟森, 扈晓宇, 等. 扶正祛邪法联合TACE对中晚期肝癌患者生存质量影响的系统评价[J]. 中西医结合研究, 2010, 2(3): 116-121. doi: 10.3870/j.issn.1674-4616.2010.03.002 [11] 张华兵, 李雪峰. 静脉滴注华蟾素注射液配合肝癌介入治疗的疗效观察[J]. 中国现代药物应用, 2012, 6(6): 77-78. doi: 10.3969/j.issn.1673-9523.2012.06.067 [12] 赵成, 张蕴超. 榄香烯注射液联合介入化疗治疗原发性肝癌的临床研究[J]. 疑难病杂志, 2012, 11(11): 882-883. https://www.cnki.com.cn/Article/CJFDTOTAL-YNBZ201211041.htm [13] 张弦, 戴家应. 中医综合干预对肝癌介入治疗患者周边症状及生存期的影响[J]. 湖南中医杂志, 2012, 28(1): 2-11. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZO201201003.htm [14] 姚世英. 中医药在肝癌介入术后减毒增效上的研究进展[J]. 海峡药学, 2011, 23(11): 79-82. doi: 10.3969/j.issn.1006-3765.2011.11.036 [15] 张晓前, 郭鹏, 党之俊, 等. 金龙胶囊联合介入疗法治疗原发性肝癌临床观察[J]. 介入放射学杂志, 2012, 21(3): 249-251. doi: 10.3969/j.issn.1008-794X.2012.03.020 -
点击查看大图
计量
- 文章访问数: 47
- HTML全文浏览量: 7
- PDF下载量: 2
- 被引次数: 0
下载:
